Motley Fool
This Biotech Stock Winner Is Up 72%, but a $4 Million Trim Signals a Slight Reset
📊
AI Sentiment
Positive
6/10
- Home
- SNDX
as of 03-23-2026 2:20pm EST
$24.33
+$0.15
+0.62%
Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Its product candidates include revumenib and axatilimab. It is developing revumenib, a selective menin-MLL inhibitor for KMT2A-rearranged (MLL-r) and NPM1-mutant acute leukemias, including ALL and AML. It is also developing axatilimab, a CSF-1R-blocking antibody for cGVHD and idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells. The business activity of the group is functioned through the region of the United States.
| Founded: | 2005 | Country: | United States |
| Employees: | N/A | City: | NEW YORK |
| Market Cap: | 1.8B | IPO Year: | 2014 |
| Target Price: | $84.17 | AVG Volume (30 days): | 1.3M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 12 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -3.29 | EPS Growth: | 11.56 |
| 52 Week Low/High: | $8.59 - $25.44 | Next Earning Date: | 05-04-2026 |
| Revenue: | $172,352,000 | Revenue Growth: | 627.84% |
| Revenue Growth (this year): | 112.05% | Revenue Growth (next year): | 51.24% |
| P/E Ratio: | -7.35 | Index: | N/A |
| Free Cash Flow: | -323167000.0 | FCF Growth: | N/A |
AI-Powered SNDX Daily Prediction
Machine learning model trained on 25+ technical indicators
Updated 19 hours ago
AI Recommendation
hold
Model Accuracy: 71.70%
71.70%
Confidence
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of Syndax Pharmaceuticals Inc. (SNDX)
Goldan Keith A.
Sell
Chief Financial Officer
SNDX Feb 9, 2026
Avg Cost/Share
$21.03
Shares
3,410
Total Value
$71,705.48
Owned After
140,429
SEC Form 4
Metzger Michael A
Sell
Chief Executive Officer
SNDX Feb 9, 2026
Avg Cost/Share
$21.03
Shares
17,159
Total Value
$360,819.45
Owned After
491,690
SEC Form 4
Goldan Keith A.
Sell
Chief Financial Officer
SNDX Feb 6, 2026
Avg Cost/Share
$20.62
Shares
2,082
Total Value
$42,930.84
Owned After
140,429
SEC Form 4
Metzger Michael A
Sell
Chief Executive Officer
SNDX Feb 6, 2026
Avg Cost/Share
$20.62
Shares
7,412
Total Value
$152,835.44
Owned After
491,690
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Goldan Keith A. | SNDX | Chief Financial Officer | Feb 9, 2026 | Sell | $21.03 | 3,410 | $71,705.48 | 140,429 | |
| Metzger Michael A | SNDX | Chief Executive Officer | Feb 9, 2026 | Sell | $21.03 | 17,159 | $360,819.45 | 491,690 | |
| Goldan Keith A. | SNDX | Chief Financial Officer | Feb 6, 2026 | Sell | $20.62 | 2,082 | $42,930.84 | 140,429 | |
| Metzger Michael A | SNDX | Chief Executive Officer | Feb 6, 2026 | Sell | $20.62 | 7,412 | $152,835.44 | 491,690 |
Earnings Transcripts
SEC 8-K filings with transcript text
2025 Q4 Q4 2025 Earnings
8-K BUY Feb 26, 2026 · 100% conf.
2025
Q4
Q4 2025 Earnings
8-K BUYFeb 26, 2026 · 100% conf.
AI Prediction BUY
1D
+7.63%
$22.25
Act: +4.23%
5D
+9.42%
$22.62
Act: +4.40%
20D
+21.05%
$25.02
Price: $20.67 Prob +5D: 100% AUC: 1.000
0001193125-26-076522
8-K
0001395937false00013959372026-02-262026-02-26
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): February 26, 2026
SYNDAX PHARMACEUTICALS, INC.
(Exact name of Registrant as Specified in Its Charter)
Delaware
001-37708
32-0162505
(State or Other Jurisdiction of Incorporation)
(Commission File Number)
(IRS Employer Identification No.)
730 THIRD AVENUE
FLOOR 9
NEW YORK, New York
10017
(Address of Principal Executive Offices)
(Zip Code)
Registrant’s Telephone Number, Including Area Code: (781) 419-1400
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common Stock
SNDX
The Nasdaq Stock Market LLC
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02. Results of Operations and Financial Condition.
On February 26, 2026, Syndax Pharmaceuticals, Inc. (the “Company”) issued a press release and presentation announcing its financial results for the quarter and year ended December 31, 2025. A copy of the press release and presentation are furnished as Exhibits 99.1 and 99.2 to this Current Report on Form 8-K and are incorporated herein by reference.
The information contained in this Item 2.02 and in Exhibits 99.1 and 99.2 attached hereto is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any of the Company’s filings under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.
Item 9.01. Financial Statements and Exhibits. (d) Exhibits.
Exhibit No.
Description
99.1
Press Release, dated February 26, 2026
99.2
Corporate Presentation, dated February 26, 2026
104
Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
SYNDAX PHARMACEUTICALS, INC.
By:
/s/ Michael A. Metzger
Michael A. Metzger
Chief Executive Officer
Dated: February 26, 2026
2025 Q4 Q4 2025 Earnings
8-K BUY Jan 12, 2026 · 100% conf.
2025
Q4
Q4 2025 Earnings
8-K BUYJan 12, 2026 · 100% conf.
AI Prediction BUY
1D
+7.63%
$22.25
Act: +4.23%
5D
+9.42%
$22.62
Act: +4.40%
20D
+21.05%
$25.02
Price: $20.67 Prob +5D: 100% AUC: 1.000
0001193125-26-010486
8-K
0001395937false00013959372026-01-122026-01-12
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): January 12, 2026
SYNDAX PHARMACEUTICALS, INC.
(Exact name of Registrant as Specified in Its Charter)
Delaware
001-37708
32-0162505
(State or Other Jurisdiction of Incorporation)
(Commission File Number)
(IRS Employer Identification No.)
730 THIRD AVENUE
FLOOR 9
NEW YORK, New York
10017
(Address of Principal Executive Offices)
(Zip Code)
Registrant’s Telephone Number, Including Area Code: (781) 419-1400
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common Stock
SNDX
The Nasdaq Stock Market LLC
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition. On January 12, 2026, Syndax Pharmaceuticals, Inc. (the “Company”) issued a press release in connection with the Company’s presentation on the same date at the 44th Annual J.P. Morgan Healthcare Conference that contains certain preliminary financial information as of and for the fiscal year ended December 31, 2025. Specifically, the press release states that (i) the Company achieved approximately $44 million and $125 million in preliminary (unaudited) U.S. net product revenue for Revuforj® (revumenib) for fiscal quarter and year ended December 31, 2025, respectively, (ii) Niktimvo™ (axatilimab-csfr) achieved $56 million and $152 million in preliminary (unaudited) U.S. net product revenue for fiscal quarter and year ended December 31, 2025, respectively, and the Company will report it’s share of net commercial profit when it reports full year 2025 results, and (iii) the Company’s total preliminary cash, cash equivalents and marketable securities (unaudited) was approximately $394 million as of December 31, 2025.
The information in this Item 2.02 is unaudited and preliminary, and does not present all information necessary for an understanding of the Company’s results of operations for the fiscal year ended December 31, 2025, or financial condition as of December 31, 2025. The preliminary selected financial results reported by the Company for the fourth quarter and full-year 2025 are provided only as an approximation in advance of the Company’s announcement of complete financial results in early 2026. This information is based on currently available information. The audit of the Company’s financial statements for the year ended December 31, 2025 is ongoing and could result in changes to the information in this Item 2.02. Item 7.01 Regulation FD Disclosure. The disclosure in Item 2.02 above is hereby incorporated by reference into this Item 7.01.
The information contained in Item 2.02 and 7.01, as well as Exhibit 99.1, to this Current Report on Form 8-K shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing. Item 9.01 Financial Statements and Exhibits. (d) Exhibits
Exhibit No.
Description
99.1
Press Release dated January 12, 2026
104
Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
SYNDAX PHARMACEUTICALS, INC.
Date:
January 12, 2026
By:
/s/ Michael A. Metzger
Michael A. Metzger Chief Executive
2025 Q3 Q3 2025 Earnings
8-K Nov 3, 2025
2025
Q3
Q3 2025 Earnings
8-KNov 3, 2025
0001193125-25-262509
8-K
0001395937false00013959372025-11-032025-11-03
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): November 03, 2025
SYNDAX PHARMACEUTICALS, INC.
(Exact name of Registrant as Specified in Its Charter)
Delaware
001-37708
32-0162505
(State or Other Jurisdiction of Incorporation)
(Commission File Number)
(IRS Employer Identification No.)
730 THIRD AVENUE
FLOOR 9
NEW YORK, New York
10017
(Address of Principal Executive Offices)
(Zip Code)
Registrant’s Telephone Number, Including Area Code: (781) 419-1400
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common Stock
SNDX
The Nasdaq Stock Market LLC
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02. Results of Operations and Financial Condition.
On November 3, 2025, Syndax Pharmaceuticals, Inc. (the “Company”) issued a press release and presentation announcing its financial results for the quarter and six months ended September 30, 2025. A copy of the press release and presentation are furnished as Exhibits 99.1 and 99.2 to this Current Report on Form 8-K and are incorporated herein by reference.
The information contained in this Item 2.02 and in Exhibits 99.1 and 99.2 attached hereto is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any of the Company’s filings under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.
Item 9.01. Financial Statements and Exhibits. (d) Exhibits.
Exhibit No.
Description
99.1
Press Release, dated November 3, 2025
99.2
Corporate Presentation, dated November 3, 2025
104
Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
SYNDAX PHARMACEUTICALS, INC.
By:
/s/ Michael A. Metzger
Michael A. Metzger
Chief Executive Officer
Dated: November 3, 2025
Latest Syndax Pharmaceuticals Inc. News
SNDX Breaking Stock News: Dive into SNDX Ticker-Specific Updates for Smart Investing
Motley Fool
High-Flying Biotech Stock Up 360% Faces $48 Million Trim but Remains This Fund's Largest Holding
📊
AI Sentiment
Positive
7/10
Motley Fool
This Fund Just Cut a Viridian Stock Position by Over $80 Million. Here's What Investors Should Know
➖
AI Sentiment
Neutral
4/10
Motley Fool
This Biotech Stock Up 135% Just Faced a $44 Million Trim. Here's What Investors Should Know
➖
AI Sentiment
Neutral
4/10
Motley Fool
Biotech Stock Up 72% Sees $8 Million Sale, but Here's Why One Fund Still Seems Bullish
📊
AI Sentiment
Positive
7/10
Simply Wall St.
Is It Time To Reassess Syndax Pharmaceuticals (SNDX) After Its 88.5% One Year Surge?
📈
AI Sentiment
Highly Positive
8/10
Compare SNDX vs Leading Stocks
See how SNDX stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "SNDX Syndax Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.